Novo Nordisk Warns of Sales Decline as Generic Semaglutide Threatens Canadian Market

Novo Nordisk’s Q4 2025 earnings report revealed several warning signs for the company’s near-term outlook:

• 2026 revenue guidance: The company forecasted a 5–13% decline in total sales for the year, driven primarily by loss of semaglutide market exclusivity.
• CEO statement: Lars Fruergaard Jørgensen told analysts that “it will get worse before it gets better,” referencing the anticipated entry of generic semaglutide competitors in multiple markets.
• Share price reaction: Novo Nordisk shares fell 17–18% on the Copenhagen Stock Exchange following the earnings call, reflecting investor concern about the company’s ability to maintain pricing power.

The magnitude of the share decline — one of the largest single-day drops in Novo Nordisk’s history — underscored how central semaglutide exclusivity has been to the company’s valuation.

Novo Nordisk’s semaglutide data exclusivity has expired or is expiring in several major markets simultaneously:

• Canada: Data exclusivity expired January 4, 2026. Nine generic manufacturers have filed submissions with Health Canada.
• Brazil: Generic semaglutide applications are under review by ANVISA, Brazil’s health regulatory agency.
• China: Multiple Chinese manufacturers have filed for generic semaglutide approval with the NMPA.

The simultaneous loss of exclusivity across these markets is what makes 2026 particularly challenging for Novo Nordisk. Unlike a single-market patent expiration, the company faces generic competition on multiple fronts at once.

In anticipation of generic competition, Novo Nordisk secured Health Canada approval for two new semaglutide brands on December 22, 2025:

These are not generics. Plosbrio and Poviztra contain the identical formulation as Ozempic and Wegovy, respectively, but are marketed under new brand names. This strategy allows Novo Nordisk to offer lower price points without reducing the listed price of its flagship brands — a common pharmaceutical tactic known as an “authorized brand.”

Health Canada has confirmed that Plosbrio and Poviztra “are not generic semaglutide products and have no connection to Health Canada’s review of the generic semaglutide submissions.” For full details, see our post on Plosbrio and Poviztra in Canada.

As of February 2026, nine companies have submitted generic semaglutide applications to Health Canada. The known applicants include:

• Sandoz — targeting Q3 2026 launch
• Apotex — Canada’s largest generic manufacturer
• Teva Pharmaceutical
• Taro Pharmaceutical
• Dr. Reddy’s — received Notice of Non-Compliance (first rejection); expected to resubmit
• Aspen Pharmacare
• Vimy Pharma

The volume of applications is notable. In Canadian generic drug history, having nine manufacturers file for the same product signals strong commercial interest and suggests aggressive pricing competition once approvals are granted.

Based on historical Canadian generic pricing patterns and early manufacturer signals, generic semaglutide is expected to be priced significantly below branded Ozempic:

These are estimates based on historical Canadian generic pricing patterns. Actual prices will be determined by manufacturers and pharmacies after approval.

The combination of Novo Nordisk’s financial pressure and the wave of generic applications points to meaningful price relief for Canadians taking semaglutide:

• Plosbrio and Poviztra could arrive first. Already approved by Health Canada, these Novo Nordisk authorized brands may reach pharmacy shelves before generic competitors clear the regulatory process. Their pricing has not been announced, but they are expected to undercut Ozempic and Wegovy.
• Generic competition drives prices down further. Once multiple generic manufacturers receive Health Canada approval, price competition historically accelerates. The nine applications suggest robust competition is coming.
• Provincial formulary changes may follow. Provincial drug plans set their own formulary listings and pricing rules. Generic availability often triggers formulary reviews and expanded coverage, though the timing varies by province.
• Real price relief is coming in 2026. Whether through Plosbrio, Poviztra, or generic semaglutide, the era of a single-manufacturer semaglutide market in Canada is ending. The question is no longer if prices will drop, but when and by how much.

Several developments in the coming months will determine how quickly price relief materializes:

• Novo Nordisk’s pharmacy launch dates for Plosbrio and Poviztra
• Health Canada approval decisions on generic semaglutide submissions
• Sandoz’s Q3 2026 launch timeline and any further changes
• Provincial formulary listing announcements
• Actual pharmacy pricing once new products reach the market

GLP1Prices.ca will publish verified prices for all new semaglutide products as soon as they become available at Canadian pharmacies. To be notified when generic or lower-cost semaglutide prices go live, sign up for our generic price alert.